Non Small Cell Lung Cancer

65 competing products in clinical development for Non Small Cell Lung Cancer.

Pipeline by Phase

Pre-clinical4

Phase 18

Phase 1/28

Phase 223

Phase 322

All Products (65)

Product	Company	Stage	Status	Hype
Divarasib + Pembrolizumab + Pemetrexed + Carboplatin + Cisplatin	Chugai Pharmaceutical	Phase 3	Recruiting	47
Datopotamab Deruxtecan + Rilvegostomig + Pembrolizumab	Daiichi Sankyo	Phase 3	Recruiting	47
Trastuzumab Deruxtecan + pembrolizumab + Pemetrexed + Chemotherapy	Daiichi Sankyo	Phase 3	Recruiting	47
Osimertinib + Datopotamab Deruxtecan	Daiichi Sankyo	Phase 3	Recruiting	47
Divarasib + Sotorasib + Adagrasib	Chugai Pharmaceutical	Phase 3	Active	44
Lazertinib 240 mg/160 mg + Gefitinib 250 mg + Lazertinib-matching placebo 240 mg/160 mg + Gefitinib-matching placebo 250 mg	Yuhan	Phase 3	Active	44
Datopotamab Deruxtecan + Rilvegostomig + Carboplatin + Cisplatin + Etoposide + Pemetrexed + Vinorelbine + UFT	Daiichi Sankyo	Phase 3	Active	44
DS-1062a + Docetaxel	Daiichi Sankyo	Phase 3	Active	44
Neoadjuvant lazertinib	Yuhan	Phase 2	Recruiting	42
Pembrolizumab + Carboplatin + Paclitaxel + Nab-paclitaxel + Pemetrexed + HER3-DXd	Daiichi Sankyo	Phase 2	Recruiting	42
Rilvegostomig + Ramucirumab + Dato-DXd	Daiichi Sankyo	Phase 2	Recruiting	42
Pemetrexed + Cisplatin + Placebo + Pemetrexed	Eli Lilly	Phase 3	Completed	40
pemetrexed + docetaxel	Eli Lilly	Phase 3	Completed	40
Erlotinib + Placebo	Astellas Pharma	Phase 3	Completed	40
Exisulind	Astellas Pharma	Phase 3	Completed	40
bexarotene with carboplatin and paclitaxel + carboplatin and paclitaxel	Eisai	Phase 3	Completed	40
bexarotene	Eisai	Phase 3	Completed	40
Pembrolizumab + Lenvatinib + Placebo for lenvatinib	Eisai	Phase 3	Completed	40
Pembrolizumab + Lenvatinib + Placebo for lenvatinib	Eisai	Phase 3	Completed	40
Nivolumab + Ipilimumab + Carboplatin + Cisplatin + Gemcitabine + Pemetrexed + Paclitaxel	Ono Pharmaceutical	Phase 3	Completed	40
ONO-4538 + Carboplatin + Paclitaxel + Bevacizumab + Placebo	Ono Pharmaceutical	Phase 3	Completed	40
Nivolumab + Cisplatin + Vinorelbine + Gemcitabine + Docetaxel + Pemetrexed + Carboplatin + Paclitaxel + Ipilimumab	Ono Pharmaceutical	Phase 3	Completed	40
TNG456 + abemaciclib	Eli Lilly	Phase 1/2	Recruiting	39
valemetostat tosylate + pembrolizumab	Daiichi Sankyo	Phase 1/2	Recruiting	39
PemCarbo + Pem only	Eli Lilly	Phase 3	UNKNOWN	36
pemetrexed + erlotinib	Eli Lilly	Phase 2	Completed	35
enzastaurin + pemetrexed + docetaxel + carboplatin	Eli Lilly	Phase 2	Completed	35
pemetrexed + gemcitabine	Eli Lilly	Phase 2	Completed	35
enzastaurin + placebo	Eli Lilly	Phase 2	Completed	35
pemetrexed + Best Supportive Care	Eli Lilly	Phase 2	Completed	35
Trastuzumab deruxtecan	Daiichi Sankyo	Phase 2	Completed	35
CS-1008 + Placebo + Paclitaxel + Carboplatin	Daiichi Sankyo	Phase 2	Completed	35
DS-1062a	Daiichi Sankyo	Phase 2	Completed	35
Erlotinib	Astellas Pharma	Phase 2	Completed	35
Tarceva (Trademark) (erlotinib HCl, OSI-774) + Combination carboplatin and paclitaxel	Astellas Pharma	Phase 2	Completed	35
eribulin mesylate + erlotinib + eribulin mesylate + erlotinib	Eisai	Phase 2	Completed	35
Lenvatinib + Lenvatinib matched placebo + BSC	Eisai	Phase 2	Completed	35
Nivolumab	Ono Pharmaceutical	Phase 2	Completed	35
ARQ 197	Kyowa Kirin	Phase 2	Completed	35
RO7496353 + Atezolizumab + Capecitabine + S-1 + Nivolumab + Oxaliplatin + Nab-paclitaxel + Gemcitabine	Chugai Pharmaceutical	Phase 1	Active	33
ONO-4578 + ONO-4538 + Docetaxel + Ramucirumab	Ono Pharmaceutical	Phase 1	Active	33
S-3304	Shionogi	Phase 1/2	Completed	32
eribulin mesylate + pemetrexed + Eribulin mesylate (eribulin; E7389)	Eisai	Phase 1/2	Completed	32
ARQ 197 and Erlotinib + Placebo and Erlotinib	Kyowa Kirin	Phase 3	Terminated	32
S-588410 + Placebo	Shionogi	Phase 2	UNKNOWN	31
Tomivosertib + Pembrolizumab + Pemetrexed	eFFECTOR Therapeutics	Phase 2	Active	29
YH25448 240mg	Yuhan	Phase 1	Completed	29
E7080 + E7080 + Paclitaxel + Carboplatin	Eisai	Phase 1	Completed	29
ARQ 197 and Erlotinib	Kyowa Kirin	Phase 1	Completed	29
mogamulizumab + Docetaxel	Kyowa Kirin	Phase 1	Completed	29
AC0010	Sun Pharmaceutical	Phase 1/2	UNKNOWN	28
pemetrexed + cisplatin	Eli Lilly	Phase 2	Terminated	27
Datopotamab deruxtecan	Daiichi Sankyo	Phase 2	Withdrawn	27
Trastuzumab deruxtecan	Daiichi Sankyo	Phase 2	Terminated	27
Selpercatinib	Eli Lilly	Pre-clinical	Completed	26
Pemetrexed	Eli Lilly	Pre-clinical	Completed	26
Lazertinib + Platinum-based Chemotherapy	Yuhan	Pre-clinical	Completed	26
CAB-AXL-ADC + PD-1 inhibitor	BioAtla	Phase 2	Completed	25
ASP8273	Astellas Pharma	Phase 1/2	Terminated	24
Gilteritinib + Erlotinib	Astellas Pharma	Phase 1/2	Terminated	24
FYB206 + FYB206 + Keytruda	Formycon AG	Phase 3	Terminated	22
CAB-ROR2-ADC + PD-1 inhibitor	BioAtla	Phase 1/2	Completed	22
Lazertinib	Yuhan	Pre-clinical	UNKNOWN	22
DS-1205c + Gefitinib	Daiichi Sankyo	Phase 1	Terminated	21
BBP-398 with nivolumab	BridgeBio Pharma	Phase 1	Terminated	18